Company intelligence / Profile preview

Fermion

Espoo, Uusimaa, Finlandfermion.fi ↗

Ownership: Private
Development stage: Commercial

Overview

The lead program, FZ002-037, is a highly selective oral small-molecule SSTR4 agonist for pain management. It has completed Phase I clinical trials in China with plans for Phase II in diabetic peripheral neuropathy. The pipeline includes over ten small molecule programs targeting novel mechanisms in neurology and autoimmune diseases, with several assets at IND-enabling or early clinical stages.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Simcere Pharmaceutical Group Limited

Beyond the preview

Go deeper on Fermion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fermion.

Explore the full profile